Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.

@article{Dobashi2011KinasedrivenPO,
  title={Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.},
  author={Yoh Dobashi and Shinichiro Koyama and Yoshihiko Kanai and Kenji Tetsuka},
  journal={Frontiers in bioscience},
  year={2011},
  volume={16},
  pages={1714-32}
}
Despite remarkable advances in oncology medicine, the prognosis of lung cancer patients has not greatly improved over the past few decades. To overcome the current limit, new classes of agents that specifically target particular cascades have been developed. Gefitinib and erlotinib, which are tyrosine kinase inhibitors specific for the epidermal growth… CONTINUE READING